Pemetrexed Induces S-Phase Arrest and Apoptosis via a Deregulated Activation of Akt Signaling Pathway

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer

(2014) J Greenhalgh et al.   HEALTH TECHNOLOGY ASSESSMENT

Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors

(2013) Mark E. Welker et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer

(2013) Shirish M. Gadgeel et al.   Clinical Lung Cancer

Targeting PI3K/Akt/mTOR Cascade: The Medicinal Potential, Updated Research Highlights and Challenges Ahead

(2013) X. Ma et al.   CURRENT MEDICINAL CHEMISTRY

Targeting the PI3K-AKT-mTOR signaling network in cancer

(2013) Khurum H. Khan et al.   Chinese Journal of Cancer

The Paradox of Akt-mTOR Interactions

(2013) Lakshmipathi Vadlakonda et al.   Frontiers in Oncology

Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells

(2013) Lakshmipathi Vadlakonda et al.   Frontiers in Oncology

Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma

(2012) Ravi S. Narayan et al.   CURRENT PHARMACEUTICAL DESIGN

Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance

(2012) Nitzan Gonen et al.   DRUG RESISTANCE UPDATES

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View

(2012) Martin J. Edelman et al.   Journal of Thoracic Oncology

Phosphorylation of Rad9 at Serine 328 by Cyclin A-Cdk2 Triggers Apoptosis via Interfering Bcl-xL

(2012) Zhuo Zhan et al.   PLoS One

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

(2011) E Giovannetti et al.   BRITISH JOURNAL OF CANCER

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

(2011) K Takezawa et al.   BRITISH JOURNAL OF CANCER

Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells

(2011) Tsung-Ying Yang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways

(2011) Tsung-Ying Yang et al.   MOLECULAR CARCINOGENESIS

Deubiquitinase USP37 Is Activated by CDK2 to Antagonize APCCDH1 and Promote S Phase Entry

(2011) XiaoDong Huang et al.   MOLECULAR CELL

An Important Role for CDK2 in G1 to S Checkpoint Activation and DNA Damage Response in Human Embryonic Stem Cells

(2011) Irina Neganova et al.   STEM CELLS

PI-3-K and AKT: Onto the mitochondria☆

(2009) Bangyan L. Stiles   ADVANCED DRUG DELIVERY REVIEWS

The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer

(2009) Olga C.J. Schuurbiers et al.   Journal of Thoracic Oncology

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

(2008) C Tekle et al.   BRITISH JOURNAL OF CANCER

OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis

(2008) Haiming Ding et al.   INTERNATIONAL JOURNAL OF CANCER

Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis

(2008) S. Maddika et al.   JOURNAL OF CELL SCIENCE

Unscheduled Akt-Triggered Activation of Cyclin-Dependent Kinase 2 as a Key Effector Mechanism of Apoptin's Anticancer Toxicity

(2008) S. Maddika et al.   MOLECULAR AND CELLULAR BIOLOGY

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

(2008) S. Ramalingam et al.   ONCOLOGIST